AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31302000 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle Therapy
Number of subjects: 171
Study 29085538 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated gel (102.0° F)
Number of subjects: 124
Study 29085538 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature gel (82.3° F)
Number of subjects: 124
Study 25982449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligaclips (Group A)
Number of subjects: 420
Study 25982449 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS) (Group B)
Number of subjects: 420
Study 25982449 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure (LS) (Group C)
Number of subjects: 420
Study 25982449 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Ligaclips vs LigaSure
Number of subjects: 420
Study 25982449 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HS vs Ligaclips
Number of subjects: 420
Study 25982449 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HS vs LigaSure
Number of subjects: 420
Study 23607594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus peginterferon alfa-2a and ribavirin for 12 weeks
Number of subjects: 826
Study 23607594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 826
Study 23607594 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2a plus ribavirin for 24 weeks
Number of subjects: 826
Study 23607594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin
Number of subjects: 826
Study 23607594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Number of subjects: 826
Study 23607594 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon
Number of subjects: 826
Study 21762229 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 2 mg inhalation suspension
Number of subjects: 180
Study 21762229 — intervention group
Group type: COMPARATOR
Intervention: Normal sterile saline (NSS) placebo
Number of subjects: 180
Study 19372573 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisconsin Predicting Patient's Relapse (WI‐PREPARE) measure
Number of subjects: 0
Study 19372573 — intervention group
Group type: COMPARATOR
Intervention: Fagerström Test for Nicotine Dependence (FTND)
Number of subjects: 0
Study 16293676 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMTX (5-fluorouracil + adriamycin + methotrexate with leucovorin rescue)
Number of subjects: 397
Study 16293676 — intervention group
Group type: EXPERIMENTAL
Intervention: FEMTX (5-fluorouracil + epirubicin + methotrexate with leucovorin rescue)
Number of subjects: 397
Study 16293676 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery alone)
Number of subjects: 397
Study 12858356 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously untreated prostate cancer
Number of subjects: 30
Study 12858356 — intervention group
Group type: EXPERIMENTAL
Intervention: HRPC
Number of subjects: 30
Study 12858356 — intervention group
Group type: COMPARATOR
Intervention: BPH
Number of subjects: 30
Study 10928252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical autotransfusion devices
Number of subjects: 100
Study 8956674 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (mean final dose 176 ± 149 mg/d)
Number of subjects: 21
Study 8956674 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (mean final dose 16 ± 8 mg/d)
Number of subjects: 21
Study 1285568 — intervention group
Group type: EXPERIMENTAL
Intervention: L-648,051 (6 mg, four times daily for 7 days)
Number of subjects: 10
Study 1285568 — intervention group
Group type: EXPERIMENTAL
Intervention: L-648,051 (6 mg, inhaled before antigen challenge)
Number of subjects: 10
Study 1285568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3516295 — intervention group
Group type: EXPERIMENTAL
Intervention: emepronium carrageenate (Cetiprin novum)
Number of subjects: 72
Study 28986963 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure Rush
Number of subjects: 281
Study 28986963 — intervention group
Group type: COMPARATOR
Intervention: Active control lesson
Number of subjects: 281
Study 27383395 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination maps for AD versus SCD
Number of subjects: 286
Study 27383395 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination maps for AD versus MCI
Number of subjects: 286
Study 27383395 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination maps for MCI versus SCD
Number of subjects: 286
Study 27383395 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination maps for MCI converted to AD versus SCD
Number of subjects: 286
Study 27383395 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination maps for MCI converted to AD versus stable MCI
Number of subjects: 286
Study 25571980 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma iGFR
Number of subjects: 147
Study 25571980 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary iGFR
Number of subjects: 147
Study 25571980 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma iGFR and Urinary iGFR
Number of subjects: 147
Study 22849787 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated text messaging (SMS) system providing daily queries about prescription pickup and dosage taken with educational feedback
Number of subjects: 200
Study 22849787 — intervention group
Group type: COMPARATOR
Intervention: Usual printed discharge instructions
Number of subjects: 200
Study 20537396 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (5 or 10mg BID)
Number of subjects: 0
Study 20537396 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20mg QD)
Number of subjects: 0
Study 20537396 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Asenapine
Number of subjects: 0
Study 20537396 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 0
Study 20537396 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 18197974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacilli treatment (109 freeze-dried lactobacilli for 10 days during 3 menstrual cycles)
Number of subjects: 100
Study 18197974 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (identical placebo capsules for 10 days during 3 menstrual cycles)
Number of subjects: 100
Study 18197974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacilli treatment
Number of subjects: 100
Study 18197974 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study 15924533 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal amnioinfusion
Number of subjects: 34
Study 15924533 — intervention group
Group type: COMPARATOR
Intervention: Expectant management only
Number of subjects: 34
Study 14764424 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol-fortified orange juice (sterol OJ) (2g/d)
Number of subjects: 72
Study 14764424 — intervention group
Group type: COMPARATOR
Intervention: Placebo orange juice (placebo OJ)
Number of subjects: 72
Study 11513221 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical linear modeling
Number of subjects: 2746
Study 11513221 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of variance
Number of subjects: 2746
Study 9216851 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB chemotherapy (cisplatin, vinblastine, bleomycin)
Number of subjects: 148
Study 9216851 — intervention group
Group type: COMPARATOR
Intervention: CAP chemotherapy (cyclophosphamide, aclacinomycin, cisplatin)
Number of subjects: 148
Study 9216851 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB chemotherapy
Number of subjects: 148
Study 9216851 — intervention group
Group type: COMPARATOR
Intervention: CAP chemotherapy
Number of subjects: 148
Study 8127221 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 121008
Study 8127221 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG + 5 x 10(7) killed Mycobacterium leprae
Number of subjects: 121008
Study 8127221 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG + 6 x 10(8) killed M. leprae
Number of subjects: 121008
Study 8127221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121008
Study 8127221 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (from mid-1987 onwards)
Number of subjects: 121008
Study 3492975 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem at 100 micrograms/kg (D-100)
Number of subjects: 63
Study 3492975 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (various doses)
Number of subjects: 63
Study 3492975 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem at 50 micrograms/kg (D-50) and 100 micrograms/kg (D-100)
Number of subjects: 63
Study 3492975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 29879968 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-week supervised exercise program
Number of subjects: 128
Study 29879968 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 128
Study 27788313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 150
Study 27788313 — intervention group
Group type: COMPARATOR
Intervention: Control Therapy for Insomnia (CTRL)
Number of subjects: 150
Study 24999158 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Workers (CHW's) intervention with monthly visits
Number of subjects: 30
Study 24999158 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 22890910 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 84
Study 22890910 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI cases
Number of subjects: 84
Study 22890910 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 84
Study 22890910 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI patients <1 year
Number of subjects: 84
Study 22890910 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI patients >1 year
Number of subjects: 84
Study 22890910 — intervention group
Group type: EXPERIMENTAL
Intervention: Abusive head trauma (AHT) cases
Number of subjects: 84
Study 22890910 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-abusive TBI cases
Number of subjects: 84
Study 20411218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (8-week supervised rehabilitation programme)
Number of subjects: 87
Study 20411218 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 87
Study 18597921 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine devices (LNG-IUD)
Number of subjects: 60
Study 18597921 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist (GnRHa)
Number of subjects: 60
Study 16642920 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) administered at 20 ng/kg/min from just after the induction of anesthesia to the end of surgery
Number of subjects: 24
Study 16642920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGE1 treatment)
Number of subjects: 24
Study 14714362 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Chinese and Western Medicine (ICWM)
Number of subjects: 63
Study 14714362 — intervention group
Group type: COMPARATOR
Intervention: Western Medicine (Control)
Number of subjects: 63
Study 14714362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ICWM and Control)
Number of subjects: 63
Study 10813120 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferguson hemorrhoidectomy
Number of subjects: 77
Study 10813120 — intervention group
Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy
Number of subjects: 77
Study 10813120 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 77
Study 10323118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.6 mg/kg)
Number of subjects: 23
Study 10323118 — intervention group
Group type: COMPARATOR
Intervention: Oral chloral hydrate (50 mg/kg)
Number of subjects: 23
Study 1279288 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 31
Study 1279288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 4008807 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (24 mg per day)
Number of subjects: 10
Study 4008807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4008807 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (doubled dose from days 22 to 24)
Number of subjects: 10
Study 29459468 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle score based on a recently developed algorithm
Number of subjects: 240
Study 29459468 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predispositions (mutations causing monogenic hypocholesterolemia)
Number of subjects: 240
Study 29459468 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predispositions (high-weighted genetic risk score)
Number of subjects: 240
Study 29459468 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial hypercholesterolemia mutations
Number of subjects: 240
Study 29459468 — intervention group
Group type: EXPERIMENTAL
Intervention: High-weighted genetic risk score
Number of subjects: 240
Study 29459468 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle assessment
Number of subjects: 240
Study 27574913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 10
Study 25129967 — intervention group
Group type: COMPARATOR
Intervention: Modified Epley maneuver alone
Number of subjects: 147
Study 25129967 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-treatment combined with modified Epley maneuver
Number of subjects: 147
Study 25129967 — intervention group
Group type: COMPARATOR
Intervention: Hand repositioning in modified Epley-alone group
Number of subjects: 147
Study 25129967 — intervention group
Group type: COMPARATOR
Intervention: Chair-assisted repositioning in modified Epley-alone group
Number of subjects: 147
Study 25129967 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand repositioning in self-treatment group
Number of subjects: 147
Study 25129967 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair-assisted repositioning in self-treatment group
Number of subjects: 147
Study 25129967 — intervention group
Group type: COMPARATOR
Intervention: Modified Epley-alone group
Number of subjects: 147
Study 25129967 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-treatment group
Number of subjects: 147
Study 22526448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 372
Study 22526448 — intervention group
Group type: COMPARATOR
Intervention: Non-cryoanalgesia
Number of subjects: 372
Study 19889241 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (CC) (5 mg caffeine/kg body weight)
Number of subjects: 10
Study 19889241 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (DC)
Number of subjects: 10
Study 19889241 — intervention group
Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 10
Study 18620591 — intervention group
Group type: COMPARATOR
Intervention: Ringer solution (1500 ml + 200 ml mannitol + 60 ml sodium bicarbonate + 150 U/kg heparin)
Number of subjects: 140
Study 18620591 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130‐0.4 solution (1500 ml + 200 ml mannitol + 60 ml sodium bicarbonate + 150 U/kg heparin)
Number of subjects: 140
Study 16134046 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy services (short-term, free)
Number of subjects: 124
Study 16134046 — intervention group
Group type: COMPARATOR
Intervention: No advocacy services (control group)
Number of subjects: 124
Study 12462286 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% ophthalmic solution BID
Number of subjects: 185
Study 12462286 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn 2% ophthalmic solution QID
Number of subjects: 185
Study 10730526 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 4.5 mg/kg/d once daily (OD group)
Number of subjects: 49
Study 10730526 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 4.5 mg/kg/d in three divided doses (TID group)
Number of subjects: 49
Study 7670450 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate Diet (HCD) - 4.5 +/‐ 0.5 g CHO.kg‐1.d‐1 for 3 days followed by 8.2 +/‐ 0.4 g CHO.kg‐1.d‐1 for 3 days
Number of subjects: 8
Study 7670450 — intervention group
Group type: COMPARATOR
Intervention: Mixed Diet (MD) - 4.0 +/‐ 0.5 g.kg‐1.d‐1 of carbohydrate for 6 days
Number of subjects: 8
Study 2209318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive educational approach
Number of subjects: 70
Study 2209318 — intervention group
Group type: COMPARATOR
Intervention: Conventional education
Number of subjects: 70
Study 7389388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 250 mg 8-hourly
Number of subjects: 50
Study 7389388 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 250 mg 6-hourly
Number of subjects: 50
Study 31841363 — intervention group
Group type: COMPARATOR
Intervention: Standard-Dose Radiation (60 Gy) with concurrent chemotherapy
Number of subjects: 0
Study 31841363 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Radiation (74 Gy) with concurrent chemotherapy
Number of subjects: 0
Study 31841363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 0
Study 31487657 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 490
Study 31487657 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 490
Study 31487657 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 490
Study 27348462 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy via computer teleconferencing
Number of subjects: 27
Study 27348462 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy via iPhone
Number of subjects: 27
Study 27348462 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 27
Study 26418677 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First intervention
Number of subjects: 575
Study 23404724 — intervention group
Group type: EXPERIMENTAL
Intervention: PILI Lifestyle Program (PLP; n = 49)
Number of subjects: 100
Study 23404724 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavior Weight Loss Program (SBP; n = 51)
Number of subjects: 100
Study 23404724 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial weight loss in the first 3-months
Number of subjects: 100
Study 23404724 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuukese ethnicity
Number of subjects: 100
Study 21539729 — intervention group
Group type: EXPERIMENTAL
Intervention: C1,2C at baseline
Number of subjects: 133
Study 21539729 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in C2C
Number of subjects: 133
Study 21539729 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in C1,2C
Number of subjects: 133
Study 21539729 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of the standardized changes in C2C + C1,2C scores
Number of subjects: 133
Study 21539729 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in CPII
Number of subjects: 133
Study 19121466 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy and active muscular stretching
Number of subjects: 20
Study 19121466 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Myofascial Physiotherapy (Mézières method)
Number of subjects: 20
Study 19121466 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 18057480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime Proxetil (CP) 16 mg/kg/day
Number of subjects: 40
Study 18057480 — intervention group
Group type: COMPARATOR
Intervention: Cefixime (CF) 20 mg/kg/day
Number of subjects: 40
Study 15628812 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (Lantus)
Number of subjects: 196
Study 15628812 — intervention group
Group type: COMPARATOR
Intervention: NPH
Number of subjects: 196
Study 11581543 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month exercise program
Number of subjects: 100
Study 11581543 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month exercise program (long-term group)
Number of subjects: 100
Study 11581543 — intervention group
Group type: COMPARATOR
Intervention: 18-month exercise program (short-term group)
Number of subjects: 100
Study 11581543 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month to 18-month cognitive performance
Number of subjects: 100
Study 11581543 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall exercise intervention
Number of subjects: 100
Study 11006365 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (30 microg weekly intramuscular injections)
Number of subjects: 383
Study 11006365 — intervention group
Group type: COMPARATOR
Intervention: Placebo (weekly injections)
Number of subjects: 383
Study 8875379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried garlic tablets (standardised to 1.3% allicin) at a dosage of 300 mg three times daily
Number of subjects: 115
Study 8875379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 8875379 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic (from meta-analysis)
Number of subjects: 115
Study 2049420 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin 25 mgm/L
Number of subjects: 131
Study 2049420 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin 50 mgm/L
Number of subjects: 131
Study 6839757 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 101
Study 6839757 — intervention group
Group type: COMPARATOR
Intervention: Oestrogen-progestogen combination
Number of subjects: 101
Study 30879126 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 30
Study 30879126 — intervention group
Group type: COMPARATOR
Intervention: 3% saline
Number of subjects: 30
Study 30499227 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Treatment (GCBT)
Number of subjects: 198
Study 30499227 — intervention group
Group type: COMPARATOR
Intervention: Group Present-Centered Treatment (GPCT)
Number of subjects: 198
Study 30499227 — intervention group
Group type: EXPERIMENTAL
Intervention: GCBT and GPCT
Number of subjects: 198